In addition, Archemix has elevated Page Bouchard (above) to lead its research and preclinical development group. Dr. Bouchard joined Archemix in November 2004 as senior vice president of preclinical drug discovery and development. “Page possesses the unique combination of scientific experience and leadership skills necessary to guide our rapidly expanding pipeline of therapeutic aptamers through research and preclinical development,” says Archemix president and CEO Errol De Souza. “We are privileged to have a leader of his caliber directing our R&D efforts.”
Genomic Vision (Paris) has appointed founder Aaron Bensimon as president and CEO. He will be assisted by Daniel Nerson, who has been named chief operating officer. Dr. Bensimon has been head of the genome stability unit at the Institut Pasteur since 1994, where he developed molecular combing technology and its use in the precise study of genomes. The technology has resulted in 13 patents granted to the Institut Pasteur, for which Genomic Vision has an exclusive license.
This is a preview of subscription content, access via your institution